We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+15.12%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$161M
Cap. Flow
+$136M
Cap. Flow %
30.92%
Top 10 Hldgs %
58.73%
Holding
304
New
134
Increased
38
Reduced
45
Closed
43

Top Buys

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$33.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.5M
3
CYTK icon
Cytokinetics
CYTK
+$17.6M
4
ROIV icon
Roivant Sciences
ROIV
+$16.6M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$15.9M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$20.8M
2
RPRX icon
Royalty Pharma
RPRX
+$17.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$10.7M
4
MRK icon
Merck
MRK
+$6.62M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Communication Services 1.03%
3 Financials 0.65%
4 Materials 0.49%
5 Consumer Discretionary 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
176
Regenxbio
RGNX
$708M
$52.7K 0.01%
+2,500
New +$44.5K
KWEB icon
177
KraneShares CSI China Internet ETF
KWEB
$5.67B
$52.5K 0.01%
2,000
– –
KYNB
178
Kyntra Bio
KYNB
$29.4M
$50.2K 0.01%
+854
New +$36.8K
OVID icon
179
Ovid Therapeutics
OVID
$491M
$50.2K 0.01%
16,446
+3,200
+24% +$10.7K
IMA
180
ImageneBio Inc
IMA
$64.6M
$49.7K 0.01%
+2,917
New +$53.1K
AMPY icon
181
Amplify Energy
AMPY
$166M
$46.8K 0.01%
7,081
– –
PHVS icon
182
Pharvaris
PHVS
$2.44B
$46.2K 0.01%
+2,000
New +$53.1K
INSM icon
183
PUT
Insmed
INSM
$28.6B
$46.1K 0.01%
+1,700
New +$47.6K
UCTT
184
Ultra Clean Holdings
UCTT
$3.95B
$45.9K 0.01%
+1,000
New +$40.6K
AKRO
185
DELISTED
Akero Therapeutics
AKRO
$45.6K 0.01%
1,807
-14,193
-89% -$341K
ANAB icon
186
CALL
AnaptysBio
ANAB
$1.68B
$45K 0.01%
+2,000
New +$47.4K
VRDN icon
187
Viridian Therapeutics
VRDN
$2.67B
$44.6K 0.01%
+2,550
New +$49.4K
ELEV
188
DELISTED
Elevation Oncology
ELEV
$44.3K 0.01%
+8,629
New +$28K
PYXS icon
189
Pyxis Oncology
PYXS
$236M
$42.6K 0.01%
+10,000
New +$42.1K
ARQT icon
190
Arcutis Biotherapeutics
ARQT
$3.18B
$42.2K 0.01%
4,254
-270,746
-98% -$2.02M
DNLI icon
191
Denali Therapeutics
DNLI
$3.94B
$41K 0.01%
+2,000
New +$37.6K
ADVM
192
DELISTED
Adverum Biotechnologies
ADVM
$39.6K 0.01%
+2,800
New +$42.6K
MRK icon
193
Merck
MRK
$318B
$39.6K 0.01%
300
-53,700
-99% -$6.62M
STOK icon
194
Stoke Therapeutics
STOK
$2.11B
$39.1K 0.01%
+2,900
New +$17.6K
MX icon
195
Magnachip Semiconductor
MX
$145M
$39.1K 0.01%
7,000
– –
IGMS
196
DELISTED
IGM Biosciences
IGMS
$38.6K 0.01%
+4,000
New +$46.4K
BBIO icon
197
PUT
BridgeBio Pharma
BBIO
$16.5B
$37.1K 0.01%
+1,200
New +$40.8K
ASLN
198
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$36.5K 0.01%
+7,424
New +$37.2K
ETNB
199
DELISTED
89bio
ETNB
$35.6K 0.01%
3,060
+2,630
+612% +$29.1K
HOOK
200
DELISTED
HOOKIPA Pharma
HOOK
$35.6K 0.01%
+5,000
New +$35.6K
6 7
8
9 10

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, ADAR1 Capital Management held 304 positions worth $441M, up 58% from $280M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

ADAR1 Capital Management deployed $136M of net new capital in Q1 2024, opening 134 new positions and adding to 38 existing holdings. Its largest new stake was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 69% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $20.8M trimmed.

  • ADAR1 Capital Management's largest Q1 2024 buy was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.
  • ADAR1 Capital Management added most to Alnylam Pharmaceuticals in Q1 2024, an estimated $28.5M increase.
  • ADAR1 Capital Management's biggest Q1 2024 reduction was Keros Therapeutics, cutting an estimated $20.8M.
  • ADAR1 Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 59% of its $441M portfolio in Q1 2024.
  • ADAR1 Capital Management opened 134 new positions and closed 43 in Q1 2024.
  • ADAR1 Capital Management's portfolio value rose 58% quarter-over-quarter to $441M.

Based on ADAR1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.